CBT After Esketamine Cuts Relapse Risk, Trial Finds

What the Study Found

A newly published randomized controlled trial — the CBT-ENDURE study, appearing in the Journal of Clinical Psychiatry in May 2026 — has provided some of the clearest evidence yet that psychotherapy following ketamine-based treatment meaningfully extends and deepens clinical gains. The trial enrolled adults with major depressive disorder (MDD) and active suicidal ideation, a population that faces some of the most urgent and difficult-to-treat presentations in psychiatry. Participants received esketamine (the intranasal, FDA-approved form of ketamine marketed as Spravato) and were then randomized to either a 16-week structured course of cognitive behavioral therapy (CBT) or a control condition without CBT.

The results favored the combination: patients who completed the CBT course showed significantly greater reductions in both suicidal ideation and depression severity compared to those who received esketamine alone. These improvements were not marginal — the differences were clinically meaningful across the outcome measures used, which included validated scales for suicidality and depressive symptom burden. The implication is that esketamine's well-documented acute benefits, which can emerge within hours to days, may be substantially more durable when followed by a structured, evidence-based psychotherapy program. You can read the full trial report at the Journal of Clinical Psychiatry.

Esketamine vs. Low-Dose Ketamine: The Key Distinction

It is worth being precise about what was studied here. Esketamine (Spravato) is an intranasal formulation of the S-enantiomer of ketamine, administered under clinical supervision at approved doses for treatment-resistant depression and MDD with suicidal ideation. Low-dose oral or sublingual ketamine, which many readers of this site are researching or currently using, is a related but distinct treatment pathway — different route of administration, different pharmacokinetics, and a different regulatory and prescribing context. The neurobiological mechanisms overlap substantially, particularly around NMDA receptor modulation and rapid glutamatergic effects, but dose exposures and clinical protocols differ.

That said, the CBT-ENDURE findings are highly relevant to the broader ketamine treatment landscape. The core question the trial addresses — whether structured psychotherapy can lock in and extend the mood improvements that ketamine rapidly produces — applies regardless of whether the ketamine is delivered intranasally or orally, and regardless of whether it is esketamine specifically or racemic ketamine. The rapid but often time-limited antidepressant window that ketamine opens is a well-recognized feature of the treatment. The CBT-ENDURE trial offers evidence that this window is not just a temporary reprieve but potentially a launchpad — if patients use that window to engage in therapeutic work.

Why the Timing Matters: The Neuroplasticity Hypothesis

To understand why this combination may work, it helps to consider what ketamine does at a neurobiological level in the days and weeks after treatment. Ketamine's antidepressant effects are thought to involve rapid synaptogenesis — a burst of new synaptic connections — in prefrontal and hippocampal circuits that are often structurally compromised in chronic depression. This period of enhanced neuroplasticity may create a transient state in which the brain is more receptive to learning new patterns of thought and behavior. CBT, which is fundamentally a skills-based intervention targeting maladaptive cognitive patterns and behavioral avoidance, may be unusually effective when delivered during this window.

This is not a new hypothesis — researchers have been discussing the potential for psychotherapy to capitalize on ketamine-induced neuroplasticity for several years. But CBT-ENDURE is among the more rigorous randomized trial evidence to test it directly in a high-acuity population. The fact that the combination outperformed esketamine alone specifically on suicidal ideation outcomes is particularly notable, because suicidality is notoriously difficult to shift and sustain improvement in over time.

It also raises a practical question about treatment sequencing. Sixteen weeks is a substantial CBT commitment. The trial design suggests this therapy was delivered after an acute esketamine phase — not simultaneously. Understanding whether CBT should begin immediately following the acute treatment series, or whether some delay is appropriate, is a design question future research will need to address more precisely.

Implications for Dosing, Maintenance, and Expectations

For readers managing a low-dose ketamine regimen, the CBT-ENDURE trial has a few practical implications worth keeping in mind. First, on maintenance dosing: one common clinical challenge is that ketamine's antidepressant effects can attenuate over time, prompting either dose escalation or more frequent sessions. If psychotherapy can extend and stabilize remission, it may reduce the pressure on maintenance dosing schedules. Patients who combine ketamine with ongoing CBT may find they need fewer booster sessions to maintain a given level of symptom control — though this has not been directly tested in low-dose oral ketamine populations.

Second, on expectations: this study reinforces a realistic framing of what ketamine can and cannot do on its own. For patients with severe, recurrent depression — especially those with any history of suicidal ideation — ketamine is unlikely to represent a permanent solution in isolation. The rapid improvement it produces is real, but the work of rebuilding more adaptive thinking patterns, behavioral engagement, and relapse awareness typically requires structured support that medication alone does not provide. Setting this expectation early, and planning for it concretely, is something patients and prescribers should discuss at the outset of treatment.

Third, on evidence quality: CBT-ENDURE is a randomized trial, which is a meaningful step above observational data, case series, or expert opinion. That said, the study population (MDD with active suicidal ideation on esketamine) is specific, and extrapolating directly to patients using low-dose oral ketamine for milder or treatment-naive depression requires caution. The directional signal — that therapy plus ketamine outperforms ketamine alone — is likely generalizable in principle, but the magnitude of benefit and the optimal CBT format may differ across patient profiles. As always, individual responses to both ketamine and psychotherapy vary considerably, and what works well in a clinical trial population may not map precisely onto any given patient's experience.